India's Suven Life Sciences gains after Masupirdine Phase-3 study completes patient enrollment

Suven Life Sciences

03/09/2026 08:32

** Shares of India's Suven Life Sciences SUVP.NS rise 2.1% to 380.70 rupees
** Biopharmaceutical company says it has completed patient enrollment in global Phase-3 study of Masupirdine for agitation associated with Alzheimer's dementia
** Study conducted across sites in U.S. and Europe, with patients randomized to receive Masupirdine 50 mg, 100 mg or placebo once daily for 12 weeks
** Stock more than doubles YTD


 (Reporting by Payel Das in Bengaluru)
 ((Payel.das@thomsonreuters.com))